PBMs
-
Community welcomes President Biden’s call to action to rein in high drug prices
Now is the time for Congress to answer President Biden’s call to action and pass meaningful drug pricing reform that addresses the artificially inflated cost of drugs by manufacturers, PBMs, and payer formulary relationships.
-
CEO of upstart PBM: What CVS, Cigna and other PBMs are doing in drug pricing is neither sustainable nor ethical
A.J. Loiacono was speaking at MedCity INVEST in late March in Chicago when an audience member requested him to address whether it is sustainable to have a system where after insurance a drug costs $150 for consumers whereas with GoodRx the same drug is $6. Loiacono took aim at PBMs but also didn’t spare the federal government.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
The current approach to care management is not working. PBMs must return value to the healthcare discussion
The PBM industry—a transaction-driven industry that highlights economic distribution, resting squarely on price, rebates, and discounts—has consistently let down employers and patients with models that behave like retail.
-
Consumer / Employer, Legal, SYN
Pharmacists join chorus calling for DOJ to stop Optum-Change Healthcare merger
Independent and community pharmacies seek to prevent UHG and Change merging into a “corporate monster” that will stifle competition.
-
How pharmacies can help achieve health equity
PBMs today have a tremendous opportunity to help address health disparities by shifting current drug pricing and “cost vs. access” conversations to value-based discussions.
-
MedCity Influencers, BioPharma, Community
Opioid overdoses are spiking amid the pandemic – PBMs can help combat opioid abuse and misuse
Opioid overutilization is a public health crisis, and PBMs with programs aimed at curbing abuse and educating providers can have a positive and substantial impact on clients and their members.
-
Pharma, Health Services, Health Tech
GoodRx could seek up to $969M in IPO
GoodRx priced its long-awaited IPO between $24 and $28 per share. The company could raise up to $969 million in funding.
-
PBM rebates lower premiums for healthy people, but don’t bring down drug costs, BMS chief says
A panel discussion at the 2020 J.P. Morgan Healthcare Conference brought together industry executives to talk about the issue of high drug prices. The conference concluded Thursday.
-
Trump administration ends key drug pricing proposal
The Washington Post and other outlets reported that the administration has withdrawn a proposal to end rebates between pharmacy benefit managers and drugmakers.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
HHS proposes ending safe-harbor for biopharma-pharmacy benefit manager rebates
The proposed rule, which will be officially published on Wednesday, is part of the Trump administration’s blueprint for reducing out-of-pocket drug prices. However, others have said it could raise premiums and have doubted how much power the administration truly has.
-
Pfizer to raise prices on 41 drugs despite earlier deferral on price hikes
The company emphasized that the increases mostly amount to 3-5 percent and affect only 10 percent of its portfolio, but declined to reveal which drugs are affected.
-
PBM practices harm care for cancer patients, oncology professional group says
In a position statement, ASCO said PBM practices can result in medication dispensing errors, harm physicians’ ability to treat patients and drive up costs.
-
Administration’s power to curb PBM rebates limited despite role in drug costs, experts say
Transparency in pricing negotiations is key to ensuring costs are brought down, experts say, pointing to state-level legislation to mandate it.
-
Cigna, Express Scripts shareholders approve $54 billion acquisition deal
Approval for the deal – which still needs antitrust regulators’ blessing – comes months after shareholders approved CVS-Aetna merger.
-
CVS move points to growing interest in value-based drug pricing
Value-based drug pricing appears to be on the horizon, but there are multiple possibilities for how it will be implemented, expert says.